↓ Skip to main content

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

Overview of attention for article published in Arthritis Research & Therapy, August 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
2 news outlets
twitter
4 X users
facebook
1 Facebook page
reddit
1 Redditor

Citations

dimensions_citation
59 Dimensions

Readers on

mendeley
109 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
Published in
Arthritis Research & Therapy, August 2015
DOI 10.1186/s13075-015-0707-1
Pubmed ID
Authors

György Nagy, Ronald F van Vollenhoven

Abstract

The advent of new medications and new treatment strategies for rheumatoid arthritis has made it possible to achieve remission in more patients than before. Furthermore, recent clinical trials and register studies suggest that some patients who initially required aggressive therapy may achieve biologic-free remission or even the ultimate goal of therapy, drug-free remission, resembling recovery. Here, we present a discursive review of the most important studies addressing these issues. Based on the overall results, it remains unclear if achieving biologic-free and drug-free remissions are primarily due to the natural course of the disease or to the early therapeutic intervention according to the 'window of opportunity' hypothesis. Although medication-free remission is only achievable in a small subset of patients, characterizing this patient cohort may provide important information about beneficial prognostic factors and the underlying mechanisms. In summary, in a subset of patients biologic-free and even drug-free remission can be achieved; pursuing these possibilities in practice may decrease the risk for long-term side effects and attenuate the economic burden of the disease.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Colombia 1 <1%
Singapore 1 <1%
Unknown 106 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 19%
Student > Ph. D. Student 15 14%
Other 14 13%
Student > Master 13 12%
Student > Postgraduate 9 8%
Other 20 18%
Unknown 17 16%
Readers by discipline Count As %
Medicine and Dentistry 46 42%
Immunology and Microbiology 13 12%
Biochemistry, Genetics and Molecular Biology 5 5%
Agricultural and Biological Sciences 4 4%
Nursing and Health Professions 4 4%
Other 14 13%
Unknown 23 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2021.
All research outputs
#1,918,420
of 25,371,288 outputs
Outputs from Arthritis Research & Therapy
#298
of 3,380 outputs
Outputs of similar age
#24,139
of 275,720 outputs
Outputs of similar age from Arthritis Research & Therapy
#5
of 65 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,380 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,720 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.